# A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

> **NCT01715831** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 26 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** DMARDs
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01715831
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-15
- **Primary completion:** 2016-06-06
- **Final completion:** 2016-06-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715831, "A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01715831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*